Recent Updates in Molecular Targets and Pathways in Lung Cancer

Sponsored by Daiichi Sankyo. Content independently developed by OncLive®.

EP. 1: Dr. Kim on the Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

July 13th 2022

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

EP. 2: Dr. Simon on the Evaluation of Datopotamab Deruxtecan in TROP-2–Expressing Solid Tumors

July 13th 2022

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

EP. 3: Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid Tumors

July 16th 2022

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

EP. 4: HER3 Emerges as Intriguing Treatment Target in Lung Cancer

August 3rd 2022

HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of patients who have progressed after treatment with tyrosine kinase inhibitors. Preclinical data have shown that targeting HER3 and EGFR can overcome acquired resistance to EGFR inhibition.

EP. 5: CEACAM5 Shows Great Potential as Therapeutic Target in NSCLC

September 7th 2022

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

EP. 6: Investigators Lay Groundwork for Exploring TROP-2 as a Therapeutic Target in NSCLC

October 6th 2022

Clinicians looking for additional options for the treatment of patients with non–small cell lung cancer may soon be gaining another actionable biomarker with the emergence of exciting new data concerning targeting the cell-surface glycoprotein TROP-2.

EP. 7: Inroads to Targeting HER2-Mutant Lung Cancer Begin Taking Shape

October 20th 2022

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

EP. 8: Experts on the Use of ADCs in HER2-Mutated NSCLC Treatment

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

EP. 9: Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

EP. 10: Experts on Second-Line Treatment Options for EGFR TKI-Resistant NSCLC

December 23rd 2022

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.